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Abstract
Background: Dravet syndrome is a severe form of epilepsy. Majority of patients have a mutation in SCN1A gene, which
encodes a voltage-gated sodium channel. A recent study has demonstrated that 16% of SCN1A-negative patients have
a mutation in PCDH19, the gene encoding protocadherin-19. Mutations in other genes account for only a very small
proportion of families. TSPYL4 is a novel candidate gene within the locus 6q16.3-q22.31 identified by linkage study.
Objective: The present study examined the mutations in epileptic Chinese children with emphasis on Dravet syndrome.
Methods: A hundred children with severe epilepsy were divided into Dravet syndrome and non-Dravet syndrome groups
and screened for SCN1A mutations by direct sequencing. SCN1A-negative Dravet syndrome patients and patients with
phenotypes resembling Dravet syndrome were checked for PCDH19 and TSPYL4 mutations.
Results: Eighteen patients (9 males, 9 females) were diagnosed to have Dravet syndrome. Among them, 83% (15/18) had
SCN1A mutations including truncating (7), splice site (2) and missense mutations (6). The truncating/splice site mutations
were associated with moderate to severe degree of intellectual disability (p,0.05). During the progression of disease, 73%
(11/15) had features fitting into the diagnostic criteria of autism spectrum disorder and 53% (8/15) had history of
vaccination-induced seizures. A novel PCDH19 p.D377N mutation was identified in one SCN1A-negative female patient with
Dravet syndrome and a known PCDH19 p.N340S mutation in a female non-Dravet syndrome patient. The former also
inherited a TSPYL4 p.G60R variant.
Conclusion: A high percentage of SCN1A mutations was identified in our Chinese cohort of Dravet syndrome patients but
none in the rest of patients. We demonstrated that truncating/splice site mutations were linked to moderate to severe
intellectual disability in these patients. A de novo PCDH19 missense mutation together with an inherited TSPYL4 missense
variant were identified in a patient with Dravet syndrome.
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Introduction
SCN1A is regarded as the most important epilepsy gene
associated with a spectrum of epilepsy syndromes ranging from
milder phenotypes in generalized epilepsy with febrile seizures plus
(GEFS+) to severe myoclonic epilepsy of infancy (Dravet
syndrome).
GEFS+ is inherited in an autosomal-dominant pattern [1]. It
includes a spectrum of phenotypes with mild and severe forms of
epilepsy associated with febrile and afebrile seizure. The most
severe form in GEFS+ spectrum is Dravet syndrome (DS) [2]. DS
is defined by febrile and afebrile generalized and unilateral, clonic
or tonic-clonic seizures which begin in the first year of life [3]. The
seizure begins in form of prolonged febrile seizures which may
evolve to status epilepticus [1,4,5]. Other seizure types such as
myoclonic, focal, absence and atonic seizures emerge later.
Development is normal in the first year but delayed from the
second year of life followed by cognitive and personality
impairment. Pyramidal signs and ataxia may evolve. The overall
syndrome in DS is resistant to antiepileptic drugs.
SCN1A is the gene encoding the a1 pore-forming subunit of
voltage-gated sodium channel which plays an important role for
initiating and propagating action potentials in the central nervous
system [6]. This subunit consists of four homologous domains
(D1–D4) and each domain contains 6 transmembrane segments
(S1–S6) [7]. To date, more than 600 SCN1A variants have been
identified throughout the whole gene [8]. These mutations may
alter the function of the channel leading to abnormal hyper-
excitability of neural network and resulting in epileptic seizure [9].
Although SCN1A mutations were initially identified in GEFS+
families [7], most of the mutations were found in DS patients.
Majority (70–80%) of DS patients were found to have a point
mutation or gross rearrangement in their SCN1A gene [10,11,12].
The remaining 20–30% of the patients presented with the same
severe phenotype of a high rate of epilepsy. Mutations in other
genes have been reported in these patients [13].
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Mutations in PCDH19 have been reported in patients with
epilepsy and mental retardation limited to females (EFMR), which
is X-linked and connected through unaffected transmitting males
[14,15,16]. PCDH19 encodes protocadherin-19, a protein belong-
ing to the delta-2 protocadherin subclass of the cadherin
superfamily. It is a calcium-dependent cell-cell adhesion protein
primarily expressed in the nervous system and is involved in
neuronal connections and signal transductions at the synaptic
membrane [17,18,19,20]. EFMR can be differentiated from DS
with clinical features being highly variable with the onset of
seizures ranging from 6 to 36 months, combination of febrile and
afebrile seizures and variable degree of psychomotor delay and
cognitive impairment [21,22]. In a recent study, Depienne et al
[22] identified point mutations in PCDH19 genes in a group of
SCN1A-negative patients with DS. They found that 16% of
SCN1A-negative DS patients were PCDH19-positive and PCDH19
might overall account for 5% of DS patients. Although the clinical
features of PCDH19-DS patients were slightly different from the
classical SCN1A-DS patients, their results demonstrated that
PCDH19 was involved in epileptic encephalopathies clinically
overlapping with DS.
Mutations in two other genes encoding sodium channel subunits
(SCN1B, SCN2A) and 2 genes encoding GABA receptor subunits
(GABRG2 and GABRD) have been found in a few GEFS+ families.
The discovery of more susceptibility genes is important for the
improvement of genetic diagnosis and management of epilepsy
syndromes. In a recent study, computational disease gene
prioritization based on expression pattern in Human Brain Gene
Expression Atlases was applied to evaluate the candidate genes in
previously mapped novel susceptible GEFS+ locus 6q16.3-q22.31
[23,24]. TSPYL1 and TSPYL4 genes, two members of nucleosome
assembly protein, were found to be outstanding candidates for
GEFS+. As nucleosome assembly protein can regulate gene
expression and may present a novel mechanism for disease, we
have investigated TSPYL1 and TSPYL4 sequence variations in this
study.
In the present study, SCN1A mutation analysis was performed in
100 patients recruited from the Epilepsy Clinic of Queen Mary
Hospital and Duchess of Kent Children’s Hospital, being affiliated
hospitals of the University of Hong Kong. The cohort was divided
into two groups. The first group included 18 patients who
developed severe epilepsies and were diagnosed clinically to have
DS. The second group consisted of 82 patients with other epileptic
phenotypes who did not fit into the diagnostic criteria of DS. We
aim to study the rate of SCN1A mutations in these two groups of
patients and further investigate the association between SCN1A
mutation and phenotype. In addition, mutations in TSPYL4 and
PCDH19 were identified in two patients, with one of them carrying
both PCDH19 and TSPYL4 mutations.
Methods
Ethics Statement
This study was approved by the Institutional Review Board of
the Hong Kong West Cluster and the University of Hong Kong
(IRB Ref. No.: UW 11-190). Written informed consent was
obtained from the parents of children involved in the study since
2011. Prior to 2011, documented verbal consent was obtained
from the subjects’ parents. All data were analyzed anonymously.
Patient Samples and Clinical Diagnoses
One hundred patients with epilepsy being actively followed up
in the Epilepsy Clinic of Queen Mary Hospital and Duchess of
Kent Children’s Hospital were recruited. Informed consent was
obtained from their parents. Clinical data including the age of
onset, seizure types, precipitating factors, developmental course,
and family history of seizures, imaging and EEG reports were
evaluated retrospectively. Children with autistic features were
diagnosed to be autism spectrum disorder (ASD) based on DSM
IV TR diagnostic criteria. Patients with intellectual disability (ID)
were assessed according to their scores of general/developmental
quotients as mild ID (general quotient = 50–70), moderate ID
(general quotient = 25–50) or severe ID (general quotient,25).
The DS patients were identified based on International League
Against Epilepsy (ILAE) classification (1981, 1989) and core DS
phenotypes defined by Dravet [3] including normal development
before onset of seizure, onset in the first year of age by febrile or
afebrile clonic and tonic-clonic, generalized and unilateral seizure,
often prolonged, subsequent appearance of multiple seizure types
including myoclonic, atypical absences and focal seizures and
delay in developmental and cognitive skills. DS included both
severe myoclonic epilepsy of infancy and borderline severe
myoclonic epilepsy of infancy [5]. Both the 18 DS patients and
the remaining 82 non-DS patients were screened for SCN1A
mutations. Among the non-DS patients, 25 patients (12 male, 13
female) with clinical features resembling DS but varying in two
criteria from DS phenotypes such as late seizure onset, less
intractable seizure, absence of status epilepticus, myoclonic jerks or
atypical absences were selected for PCDH19 and TSPYL4mutation
study.
Control DNA samples were extracted from blood collected from
Hong Kong Red Cross. A hundred control alleles were sequenced
to confirm the mutations detected in the present study were not
polymorphisms.
Molecular Analysis of SCN1A Gene
Polymerase chain reaction. Genomic DNA samples of the
100 patients were extracted from peripheral blood using Flexigene
DNA Kit (Qiagen GmbH, Germany). All 26 exons of SCN1A
including the splice junctions were amplified by polymerase chain
reaction (PCR) using oligonucleotide primers designed based on
the sequence of SCN1A gene on human chromosome 2 (GeneBank
accession number: NC_000002.11). PCR contained 0.1 mg of
genomic DNA as template, 5 pmol of each primer, 200 mM of
deoxyribonucleoside triphosphates, and 0.5 U HotStarTaq Plus
DNA Polymerase (Qiagen) in 1X Qiagen PCR buffer. PCR was
carried out with initial enzyme activation at 95uC for 5 minutes,
followed by 50 cycles of denaturation at 94uC for 30 seconds,
annealing at 60uC for 1 minute and extension at 72uC for
1.5 minutes, with a final extension at 72uC for 10 minutes. The
quality and quantity of PCR products were checked by
electrophoresis.
DNA sequencing. PCR products were sequenced by Bigdye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystem,
Foster City, CA) using either the original PCR primers or nested
intron flanking primers. Sequences were analyzed on a 3730xl
sequencer (Applied Biosystems). Homology analyses with SCN1A
reference sequence were performed using NCBI program
BLASTH. The numbering for each mutation was taken from
the start codon with +1 corresponding to the A of the ATG in
the reference sequence of SCN1A isoform 1 (Genbank accession
number: NM_001165963). SCN1A mutations or sequence var-
iants were discriminated from single nucleotide polymorphisms
(SNP) reported in NCBI SNP and Ensembl SNP database. Novel
mutations were verified by checking the already identified SCN1A
variants in the SCN1A Variant Database [8]. The parental DNA
was collected and sequenced to distinguish between de novo and
familial variants.
Mutations in Dravet Syndrome
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Pathogenicity assessment of mutation. Several analyses
were used to evaluate the pathogenicity of the missense mutation.
Firstly, conservative analyses were performed to predict whether
the amino acid substitutions in missense mutations affect protein
function based on the degree of conservation at the affected
residues. Human SCN1A amino acid sequences were aligned with
the paralogous and orthologous sequences by an online program
ClustalW2 Multiple Sequence Alignment (European Bioinfor-
matics Institute, EMBI, UK). The GenBank accession numbers for
amino acid alignments were NP_001159435 for human SCN1A,
NP_001035232 for human SCN2A, NP_008853 for human
SCN3A, NP_000325 for human SCN4A, NP_055006 for human
SCN8A, NP_002968 for human SCN9A, XP_001154158 for
chimpanzee SCN1A, XP_001100928 for rhesus monkey SCN2A,
NP_061203 for mouse SCN1A, NP_110502 for rat SCN1A,
XP_001252710 for cattle SCN1A, XP_422021 for fowl SCN1A,
and CAQ13572 for zebrafish SCN1A. Secondly, the mutations
were analyzed by an online sequence homology-based tool,
Sorting Intolerant from Tolerant (SIFT) (Genome Institute of
Singapore, http://sift.bii.a-star.edu.sg/) [25]. Thirdly, a web-
based program Align-GVGD (http://agvgd.iarc.fr/agvgd_input.
php) [26], was used to predict whether the mutations are
deleterious to protein functions by combining the biophysical
properties of amino acids and multiple sequence alignment [27].
We applied the multiple sequence alignment used in our
conservative analysis to Align-GVGD. Grantham Variation
determined the range of toleration at a specific amino acid
position and Grantham Deviation was the physiochemical
difference between the wild type and mutated amino acid. The
variants were classified into 7 groups (class 0, class 15, class 25,
class 35, class 45, class 55 and class 65) in the program ranging
from least likely (class 0) to most likely (class 65) to interfere the
protein function. The two mutations in intron regions close to
splice site were analyzed by another online software tools,
Automated Splice Site Analyses (Laboratory of Human Molecular
Genetics and Genomic Disorders, UWO, CA, https://splice.uwo.
ca/) [28]. The functional domains in the amino acid sequence
were defined by the database UniProt with accession number
P35498.
Molecular Analysis of PCDH19 Gene
Mutations of PCDH19 genes were screened in the 3 SCN1A-
negative DS patients and 13 female non-DS patients with clinical
features resembling DS. The 6 exons of PCDH19 gene covering
the coding regions as well as the splice junctions were amplified by
PCR using oligonucleotide primers designed based on the
sequence of PCDH19 gene on human chromosome X (GeneBank
accession number: NG_021319). PCR, DNA sequencing, homol-
ogy analysis and pathogenicity assessment were performed as
mentioned above. GenBank accession numbers for amino acid
alignments were Q8TAB3 for human PCDH19, AAI11561 for
human PCDH10, CAI17092 for human PCDH17, AAI43362 for
human PCDH18, XP_003317603 for chimpanzee PCDH19,
XP_001091349 for rhesus monkey PCDH19, Q80TF3 for mouse
PCDH19, NP001162600 for rat PCDH19, DAA13144 for cattle
PCDH19, and NP_001120991 for zebrafish PCDH19. The
mutation nomenclature was based on the PCDH19 transcript
reference sequence (GeneBank accession number: NM_020766)
and nucleotides were numbered according to the cDNA with +1
corresponding to the A of the ATG translation initiation codon in
the reference sequence. The functional domains in the amino acid
sequence were defined by the database UniProt with accession
number Q8TAB3.
Molecular Analysis of TSPYL1 and TSPYL4 Genes
Polymorphisms in both genes were extracted from the dbSNP
database. Mutations of TSPYL4 gene were checked in the 3
SCN1A-negative DS patients and 25 non-DS patients with clinical
features resembling DS. The coding sequence of TSPYL4 was
amplified by PCR using primers designed based on the reference
sequence of TSPYL4 gene on human chromosome 6 (GeneBank
accession number: NC_000006). PCR, DNA sequencing, homol-
ogy analysis and pathogenicity assessment were performed as
mentioned above. GenBank accession numbers for amino acid
alignments were NP_067680 for human TSPYL4, NP_003300 for
human TSPYL1, XP_518704 for chimpanzee TSPYL4,
NP_001181803 for rhesus monkey TSPYL4, NP_001094534 for
cattle TSPYL4, NP_084479 for mouse TSPYL4, and
NP_001012075 for rat TSPYL4. The mutation nomenclature
was based on the reference sequence (GeneBank accession no.:
NM_021648) and nucleotides were numbered according to the
cDNA with +1 corresponding to the A of the ATG translation
initiation codon.
Statistical Analysis
Chi-square test was employed to illustrate the relationship
between types of SCN1A mutations (missense mutation versus
truncating/splice site mutation) and the degree of ID of the
patients (normal to mild ID versus moderate to severe ID).
Statistical analysis was performed by statistical program PRISM
V.5.0 (GraphPad Software Inc., San Diego, CA).
Results
Clinical Diagnoses (Table 1)
Eighteen patients (9 males, 9 females) were diagnosed to have
DS. All DS patients had normal development before seizure onset
and had onset before one year of age with an average onset age of
5.4 months. All patients experienced febrile seizures and had three
or more types of seizures such as partial, generalized tonic-clonic,
tonic, clonic, absence and myclonic seizures. Prolonged seizures
(.10 min) or status epilepticus were common and 16 DS patients
had different grades of intellectual disabilities. Twelve patients
(12/18; 66%) had autistic features compatible to the clinical
diagnosis of Autism Spectrum Disorder. Eight patients (8/18;
44%) had a history of vaccination induced seizures. The remaining
82 patients were classified as non-DS patients as their clinical
features could not fulfill the diagnostic criteria of DS.
SCN1A Mutations in Patients with Dravet Syndrome
(Table 2)
Of the 18 DS patients examined, 15 (83%) were identified to
have SCN1A mutations (Table 1). Six of these mutations were
missense mutations, seven were non-sense or frameshift mutations,
and two were mutations in intronic splice donor or acceptor sites
(Table 2). These mutations spread throughout the whole SCN1A
gene. Among the 6 missense mutations, 3 missense mutations
(c.311C.T, p.A104V; c.1177C.T, p.R393C and c.4834G.A,
p.V1612I) have been reported previously [8] and 3 missense
SCN1A mutations were novel (c.1264G.A, p.V422M;
c.2378C.T, p.T793M and c.3641T.G, p.I1214R). For the 7
truncating mutations, 2 (c.1348C.T, p.Q450X and c.569G.A,
p.W190X) were reported previously [10,29] and 5 (c.1053T.A,
p.C351X; c.2214G.A, p.W738X; c.2971-2972delCTinsG,
p.L991fsX992; c.4229delA, p.N1410fsX1411; c.4558delC,
p.Q1520fsX1538) were novel. The two predicted aberrant
splicings were resulted from 2 novel mutations in intron 3
(IVS3+3A.C) and intron 21 (IV21+1G.A). Most of the
Mutations in Dravet Syndrome
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mutations were in D1 and D2 of the SCN1A protein and no
mutation were located in S4 voltage sensing segment. The types
and locations of different mutations found in the 15 DS patients
were summarized in Table 2 and Fig. 1. No SCN1A mutation was
detected in the coding region of SCN1A in the other 3 DS patient.
Parental DNAs of 14 mutation positive cases were available for
SCN1A gene analysis and 1 out of 15 cases were unavailable.
Analysis of parental DNA confirmed that 12 cases of mutations
were de novo, 2 mutations (p.V1612I and p.T793M) were inherited
maternally. As the mothers of these 2 patients had the same
mutation but remain asymptomatic, the inherited mutations do
not fully explain the phenotypes. None of the mutations were
found in 100 normal control alleles. Among the 15 DS patients
with SCN1A mutations, 8 patients (53%) had a history of seizures
following vaccinations. Three of these patients had onset of first
seizures related to vaccination. The majority (75%) of seizures
occurred after DPT vaccinations. There was no history of
vaccination-induced seizure for the 3 DS patients with no SCN1A
mutation.
PCDH19 Mutations
One of the SCN1A-negative female DS patients (case 83) was
identified to have a novel PCDH19 missense mutation in exon 1
(c.1129G.A, p.D377N) (Table 1, 2). One non-DS female patient
(case 67) was identified to have another exon 1 missense mutation
(c.1019A.G, p.N340S). She presented with severe phenotype of
epilepsy and ID overlapping with the features of DS but the onset
of seizure was 15 months. Both missense mutations caused amino
acid change in the extracellular domain of PCDH19 with p.D377N
in extracellular cadherin - 4 (EC4) domain and p.N340S in EC3
domain (Fig.1). Parental DNA of case 83 was screened and the
mutation was confirmed to be de novo. Parental DNA of the other
case was unavailable. None of the mutations were found in 100
normal control alleles.
TSPYL1 Polymorphisms (Table 3)
From NCBI dbSNP, 30 SNPs were reported in the 1314 bp
coding region of TSPYL1 gene. Among these 30 SNPs, 18 SNPs
were missense, 6 were synonymous, 3 were insertions and 3 were
frameshifts. The nucleotide changes of the 6 insertions/frameshifts
were shown in Table 3. Out of these insertions/frameshifts, 4
resulted in premature stop (rs56100880, rs80099151,
rs144384201, rs140644109) and the rest resulted in insertion/
deletion of amino acids. The 4 SNPs leading to premature stop
were expected to result in loss-of-function. As deleterious
variations in TSPYL1 were identified in the general population,
mutation screening in our patients was not performed.
TSPYL4 Variant
The DS patients (case 83) with the de novo D377N PCDH19
mutation was found to have a missense variant in TSPYL4 gene
(c.178G.C, p.G60R) (Fig.1, Table 1, 2). This variant was
maternally inherited and the patient’s mother was asymptomatic.
The variant was not found in 100 normal control alleles.
Analyses of Missense and Splice Site Mutations (Table 4)
The conservation analysis (Fig. 2) in the present study
revealed that the 6 missense SCN1A mutations, 2 PCDH19
mutations and 1 TSPYL4 variant affected highly conserved
amino acids. In addition, SIFT analyses predicted that these 9
missense mutations affected protein function. By Align-GVGD
analysis (Table 4), the 9 missense mutations were assigned a high
class and given an increase likelihood to be deleterious in
different extents (p.V1214R, p.A104V, p.R393C and p.G60R
Table 2. Summary of SCN1A, PCDH19 and TSPYL4 mutations found in 17 patients.
Gene Case
Dravet
syndrome
(+/2)
Type of
mutation Amino acid Exon Nucleotide
Location in
protein De novo
SCN1A 6 + Frameshift p.L991fsX992 16 c.2971–2972delCTinsG S6 of D2 +
77 + Frameshift p.N1410fsX1411 21 c.4229delA S5–S6 of D3 +
100 + Frameshift p.Q1520fsX1538 24 c.4558delC D3–D4 loop +
53 + Nonsense p.Q450X 9 c.1348C.T D1–D2 loop +
71 + Nonsense p.W190X 4 c.569G.A S3 of D1 +
74 + Nonsense p.W738X 13 c.2214G.A D1–D2 loop +
85 + Nonsense p.C351X 8 c.1053T.A S5–S6 of D1 N.A.
24 + Splice site 2 Intron 21 IVS21+1G.A S5–S6 in D3 +
89 + Splice site 2 Intron 3 IVS3+3A.C S2 of D1 +
40 + Missense p.T793M 13 c.2378C.T S1–S2 of D2 Maternal
46 + Missense p.A104V 2 c.311C.T N-terminus +
65 + Missense p.V1612I 25 c.4834G.A S3 of D4 Maternal
75 + Missense p.R393C 9 c.1177C.T S5–S6 of D1 +
76 + Missense p.V422M 9 c.1264G.A S6 of D1 +
94 + Missense p.I1214R 18 c.3641T.G S1 of D3 +
PCDH19 67 2 Missense p.N340S 1 c.1019A.G EC3 N.A.
83 + Missense p.D377N 1 c.1129G.A EC4 +
TSPYL4 83 + Missense p.G60R 2 c.178G.C N- to NAP Maternal
D1–D4: four homologous domains of SCN1A; S1–S6: six transmembrane segments in the four domains of SCN1A; EC: extracellular cadherin domain of PCDH19;
NAP: domain of nucleosome assembly protein of TSPYL4.
doi:10.1371/journal.pone.0041802.t002
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were classified as C65; p.N340S was classified as C45; p.V1612I
was classified as C25; p.T793M, p.V422M and p.D377N were
classified as C15). Automated Splice Site Analyses revealed that
both intronic mutations in SCN1A could abolish the splice donor
sites and caused aberrant splicing.
SCN1A Variations in Patients not Grouped under Dravet
Syndrome
No SCN1A mutations were found in the 82 non-DS patients.
Two variations resulting in amino acid substitutions (p.A464P and
p.D516N) were found in 2 out of 82 non-DS patients.
Pathogenicity assessment predicted that these two substitutions
were tolerated and less likely to interfere protein functions
(Table 4).
Intellectual Disability and SCN1A Mutation
Seven patients had truncating mutation in SCN1A gene, of
which 3 (cases 71, 74 and 85) had severe ID, 1 (case 6) had
moderate ID, 1 (case 77) had mild ID and 1 (case 53) was normal.
The 2 patients (cases 24 and 89) with splice site mutation had
moderate ID. On the other hand, 5 patients (cases 40, 46, 75, 76
and 94) with missense mutations had only mild ID and 1 of them
(case 65) had moderate ID. Chi-square test showed that there was
a relationship between types of SCN1A mutation (missense
mutation versus truncating/splice site mutation) and the degree
of ID (normal to mild ID versus moderate to severe ID) (p,0.05).
This indicated that the patients with missense mutations tend to
have less severe ID than those with either truncating or splice site
mutations (Fig. 3). The 8-month-old DS patient with truncating
mutation (case 100) was not included in this analysis as he was too
young and long term cognitive outcome was still undetermined.
Discussion
SCN1A Mutations in 15 Patients with Dravet Syndrome
In this study, we have found 9 truncating and splice site
mutations among the 15 SCN1A mutations in DS patients. Most
truncating mutations terminated the protein at first 2 domains.
Early truncating mutations are mostly associated with severe
epileptic phenotypes in DS, although in a previous study, they
caused only milder epilepsy with GEFS+ and focal seizures in 2
patients [30]. In the present study, all truncating and splice site
mutations were de novo and linked to DS with severe ID.
In contrast to the truncating and splice site mutations, the
association of missense mutations with phenotypic expression of
DS patients is more controversial. In this study, we used
conservative analysis, SIFT analysis and Align-GVGD to assess
the interference of the amino acid substitutions to the protein
Figure 1. Schematic diagram showing the location of the identified mutations in the three encoded proteins.
doi:10.1371/journal.pone.0041802.g001
Table 3. Six insertion/frameshift SNPs of TSPYL1 from NCBI
dbSNPs.
SNP Nucleotide change
rs67074252 c.520_521insGGT
rs56100880 c.521_522insGGT
rs80099151 c.522delG; c.522delGinsGGT
rs144384201 c.523_524delGT; c.523_524delGTinsGGT
rs140644109 c.527_528delTG; c.527_528delTGinsGTG
rs78371471 c.528_529insGTG
doi:10.1371/journal.pone.0041802.t003
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functions. p.V1612I has been reported in the study of Depienne
et al [10] and Herini et al [31] associated with DS. p.R393C has
been reported previously in several studies [5,10,29,32] and this
mutation was all found in SMEI patients except in the study of
Harkin et al [5] who identified the R393C mutation in a patient
with myoclonic astatic epilepsy. According to the analysis in
Depienne et al. [10] study, both p.R393C and p.V1612I
mutations alter highly conserved amino acid residues in the
protein. p.R393C substitution involves a very dissimilar change in
amino acid residue but p.V1612I substitution only has a slight
influence chemically according to Grantham distance determina-
tion. However, V1612I substitution alters amino acid in a highly
conserved ion transport sequence [10]. In the present study, Align-
GVGD analysis showed that p.V1612I substitution can possibly
affect protein function (Align-GVGD classified to C25). No
mutational analysis of p.A104V has been published previously.
We illustrated here that this mutation affects a highly conserved
amino acid which is substituted with a chemically dissimilar
residues (GD=65.28) in the N-terminus and very likely (Class
C65) to affect SCN1A protein function. Conservative analyses has
showed that the three novel mutations (p.V422M, p.T793M and
p.I1214R) change highly conserved amino acid residues in the
protein and pathogenicity assessment indicated these mutations
produce dissimilar changes in amino acids. They change protein
function in different extents and are associated with severe
phenotypes of the 3 DS patients. By contrast, the 2 substitutions
(p.A464P and p.D516N) involve less conserved amino acid
residues are predicted to be tolerated and less likely to affect
protein function. The two patients with these substitutions were
diagnosed as non-DS. These findings illustrated the significance of
pathogenicity assessments in elucidating the association of amino
acid substitutions with the clinical expression of the DS patients.
Nevertheless, the association between the clinical phenotypes
and SCN1A mutations is still poorly understood. First, it is unclear
how missense mutations can cause an epileptic phenotype similar
to truncating mutations. A possible mechanism is haploinsuffi-
ciency [10]. Heterozygosity of both loss-of-function truncating and
deleterious missense mutations can result in quantitative reduction
in normal functioning sodium channel which causes severe
phenotypes in DS [10,33]. Second, both inherited missense
mutations (p.V1612I and p.T793M) in the present study were
inherited from asymptomatic mothers. In the other reported cases
of inherited SCN1A mutations [8] including truncating mutations
[34], the transmitting parents were also asymptomatic or of mild
epileptic phenotypes. Somatic mosaicisms of the parents have been
shown to account for this phenomenon [35,36,37]. It is also
possible that SCN1A mutation is not the only factor for the
phenotypes in DS patients and other genetic background and
environmental factors are involved to produce synergistic effect to
the disease. In response to this issue, Depienne et al [11,35]
proposed the possibility of a variable expression of mutation in the
brain of asymptomatic parents. They suggested that peripheral
mosaicism like blood cells does not always reflect the neuronal
mosaicism although they showed that the clinical status of mosaic
parents correlated with the percentage (0–85%) of mutation in
their blood cells. Meisler and Kearney [33] also proposed several
factors such as developmental variability, accumulation of somatic
mutation in lifetime, environmental insults and modifier genes
which may exacerbate the phenotypes of individuals carrying
SCN1A mutations. Further investigations on other interacting
genetic, developmental and environmental elements will bring
more insight into these issues.
Interestingly, here we found no mutation in S4, the voltage
sensor region as defined by Kanai et al [38], in contrast to the
finding in Zuberi et al [12] that the missense mutations occurred
with a higher frequency in S4 region. Besides, there was no
preferential localization of mutations in S5–S6 segment, the pore
forming region, which was reported previously to have higher
frequency of missense mutations in SMEI patients [12,38]. In
agreement with our study, Depienne et al [10] also failed to
demonstrate any preferential localization in S5–S6 segment. So,
the present study did not support a relationship between the
Table 4. Pathogenicity assessment of 9 missense mutations and 2 tolerated amino acid substitutions.
Gene
Change of amino acid in
missense mutation Location in protein
Conservative
analysis* SIFT analysis{ Align-GVGD analysis
Grantham
Variation
Grantham
Deviation Class{
SCN1A p.T793M S1–S2 of D2 + + 85.08 81.04 C15
p.A104V N-terminal + + 0.00 65.28 C65
p.V1612I S3 of D4 + + 0.00 28.68 C25
p.R393C S5–S6 of D1 + + 0.00 179.53 C65
p.V422M S6 of D1 + + 0.00 20.52 C15
p.I1214R S1 of D3 + + 0.00 97.59 C65
PCDH19 p.N340S EC3 + + 0.00 46.24 C45
p.D377N EC4 + + 0.00 23.01 C15
TSPYL4 p.G60R N- to NAP + + 0.00 125.13 C65
SCN1A p.D516N D1–D2 loop 2 2 353.86 0.00 C0
p.A464P D1–D2 loop 2 2 110.77 0.00 C0
*For conservative analysis, ‘‘+’’ indicates the amino acid residue is highly conserved and ‘‘2’’ indicated it is less conserved.
{For SIFT analysis, ‘‘+’’ indicates the variant affect protein function and ‘‘2’’ indicated that it is tolerated.
{The variants were classified into 7 groups (class 0, class 15, class 25, class 35, class 45, class 55 and class 65) ranging from least likely (class 0) to most likely (class 65) to
interfere the protein function (http://agvgd.iarc.fr/classifiers.php).
D1–D4: four homologous domains of SCN1A; S1–S6: six transmembrane segments in the four domains of SCN1A; EC: extracellular cadherin domain of PCDH19;
NAP: nucleosome assembly protein domain of TSPYL4.
doi:10.1371/journal.pone.0041802.t004
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Figure 2. Evolutionary conservations of amino acid substitutions found in SCN1A, PCDH19 and TSPYL4.
doi:10.1371/journal.pone.0041802.g002
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localization of mutation and the severity of the diseases and all
SCN1A mutations are severe in DS patients.
Association of SCN1A Mutation with Intellectual Disability
and Autism Spectrum Disorder
In DS patients, developmental regression in the second year,
cognitive deficits as well as behavioral disturbances are common
[3]. In the present study, patients with missense mutations tend to
be associated with less severe ID than those with either truncating
or splice site mutation. These data suggested a possible correlation
between the type of SCN1A mutation and mental development of
DS patients. Riva et al [39] also proposed that SCN1A mutation,
rather than epilepsy, was responsible for the progressive cognitive
impairment. They showed that two DS children carrying SCN1A
truncating mutations had their cognitive performance continued
to deteriorate irrespective of the difference in their epilepsy
severities. However, the study of Ragona et al [40] failed to
demonstrate a significant difference in the cognitive outcome of 26
cases with regard to the presence and type of SCN1A mutation.
They showed that the worst cognitive outcome was associated with
early appearance of myoclonus and absences. A recent review also
suggested that modifier genes present in DS patients may be the
factor affecting the cognitive outcome [41]. Additional clinical
investigations with large sample sizes will be necessary to elucidate
the correlation between cognitive development in DS patients and
the types of SCN1A mutations.
In the present study, 11 (73%) out of 15 DS patients with SCN1A
mutation had ASD in the present study. A previous study
identified four missense mutation in SCN1A gene, one coding
mutation in SCN2A gene from different autism families [42] and
suggested that mutations in the sodium channel genes may play
a role in autism susceptibility. O’Roak et al [43] also found
a functionally deleterious SCN1A missense mutation in a patient
with sporadic ASD. These findings indicate that autism may be
one of the possible consequences of SCN1A mutation. Osaka et al
[44] identified a novel SCN1A mutations in two patients with both
seizures and psychiatric disorders including panic disorder and
Asperger syndrome. They suggested that SCN1A mutation may
contribute to the expression of psychiatric disorders in addition to
epileptic seizures and combined effect of different gene variants
may determine the ultimate phenotype of patients [33,42]. Li et al
[45] reported that the DS patients with autism had more severe ID
[45]. However, in the present study, DS patients with ASD could
have mild, moderate or severe grade of ID and there is no
association with the degree of ID. Association of SCN1A mutation
in epilepsy patients with evolving autistic features is an interesting
topic for future clinical research.
Vaccination-induced Seizures or Vaccine Induced
Encephalopathy in Patients of Dravet Syndrome with
SCN1A Mutations
In the present study, 8 DS patients with SCN1A mutations had
a history of seizures following vaccinations. Our finding elucidated
that seizures after vaccinations are common in DS patients (8/18;
44%) and it is also the case in the study of Tro-Baumann et al [46]
with 19 (27%) of 70 patients having seizures after vaccination. In
contrast, the rate of febrile seizures occurring in general
population is much lower (6–9 and 25–34 per 100,000 children)
after DPT and MMR vaccines administration [47]. The high rate
of vaccination-induced seizures in DS patients with SCN1A
mutation (53%) may be connected to the genetically determined
aberrant functioning of sodium channels. Berkovic et al [47] have
also suggested that vaccination is unlikely to be the significant
trigger of the encephalopathy in DS patients with SCN1A mutation
and avoiding vaccination will not prevent the onset of disorders.
Further genetic study on patients with vaccination-induced
seizures should be considered. Testing for SCN1A mutations will
be necessary for those infants suspected to have DS in order to
provide early management in terms of temperature and infection
controls.
PCDH19 Mutations in 2 Patients
PCDH19 is another susceptibility gene for female patients of DS.
In the present study, one of the two SCN1A-negative female DS
patients was identified to have a novel PCDH19 mutation
(p.D377N). Pathogenicity assessment showed that this mutation
changes highly conserved amino acids in EC4 domain and affects
protein function. This PCDH19-positive DS patient shared the
same clinical features with other DS patients except the absence of
both myoclonic and absence seizures. Besides, this patient had
clusters of seizures during febrile episodes which was another
distinguishing feature observed in PCDH19-positive patients as
suggested by Depienne et al [48]. The proportion of PCDH19
mutation among DS patients (5.6%) in the present study was
comparable to Depienne et al. [22] study. Depienne et al [22]
suggested that PCDH19 might contribute significantly to epileptic
encephalopathies with clinical spectrum overlapping that of DS.
They showed that PCDH19-DS and SCN1A-DS had many
common features including early onset of seizures, association of
generalized tonic-clonic and focal seizures, prolonged seizures and
developmental regression. But they differed slightly as PCDH19-
DS might have a later seizure onset, less intractable seizure,
absence of status epilepticus, myoclonic jerks/atypical absences
and less severe intellectual/language delay.
Another PCDH19 mutation (p.N340S) was found in a non-DS
patient. Both patients with a PCDH19 mutation shared similar
clinical features including the presence of both partial and
generalized seizure types, occurrence of status epilepticus and
mental retardation. However, the non-DS patients had seizure
onset after 1 year (15 months). p.N340S has been reported
previously in three studies [22,49,50]. In the studies of Depienne
et al [22] and Marini et al [49], the patients with p.N340S
mutations were diagnosed as DS. However, the sister pair with this
Figure 3. Degree of intellectual disability (ID) of patients with
different types of SCN1A mutations. The number above the bar
chart indicated the number of DS patients in that group. ID: Intellectual
disability; Mild ID: general/developmental quotient = 50–70; Moderate
ID: general/developmental quotient = 25–50; Severe ID: general/de-
velopmental quotient,25.
doi:10.1371/journal.pone.0041802.g003
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mutation in the study of Dibben et al [50] were diagnosed as
EFMR. They had seizure onset at 13 and 17 months, refractory
seizure and developmental slowing. Patients with PCDH19
mutations in other studies [15,16,48] were also shown to be
non-DS with seizure onsets after 1 year. Taken together, in
addition to DS patients, PCDH19 mutation screening should also
be considered for patients with clinical features resembling DS
with seizure onset after 1 year old.
TSPYL4 Variant in 1 Patient
Interestingly, a new TSPYL4 variant was found in a DS patient
with a novel PCDH19 p.D377N mutation. The amino acid
substitution p.G60R occurs in a highly conserved amino acid and
is likely to interfere with protein function according to pathoge-
nicity assessment. Nevertheless, it is N-terminal to the conserved
nucleosome assembly protein domain. In addition, the DS patient
with the TSPYL4mutation is also PCDH19-positive and his mother
carrying the TSPYL4 mutation is asymptomatic. Besides, the role
of TSPYL4 in epilepsy has not been reported previously. Taken
together, the TSPYL4 variant we identified is unlikely to be
pathogenic.
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